RxDoctor Payments Data

Richard White, MD

Family Medicine · Lorain, OHNPI 1164637609

Payments from drug & device makers

$2,797in general payments, 2019–2025

Across 199 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$519
  • Amgen$238
  • Novo Nordisk$217
  • Siemens Medical Solutions USA, Inc.$195
  • Novartis$181
  • Pfizer$164
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,797 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$79,390
Medicare patients
393
Services billed
25,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$131,890
JanuviaSitagliptin Phosphate76$91,106
JardianceEmpagliflozin58$66,280
EliquisApixaban62$63,563
RybelsusSemaglutide26$60,465
XareltoRivaroxaban38$37,168
JanumetSitagliptin Phos/Metformin Hcl23$35,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$31,041
TrulicityDulaglutide16$22,309
LinzessLinaclotide15$13,614
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$13,052
Breo ElliptaFluticasone/Vilanterol11$8,915
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,667
OxycontinOxycodone Hcl12$6,873
Combivent RespimatIpratropium/Albuterol Sulfate13$6,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$217$192,355100 claims
MerckJanuvia, Janumet$144$126,77799 claims
Boehringer IngelheimJardiance, Combivent Respimat$14$72,87871 claims
PfizerEliquis$164$63,56362 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$37$53,00952 claims
Johnson & JohnsonXarelto$152$37,16838 claims
Lilly USA, LLCTrulicity$163$22,30916 claims
AbbVieLinzess, Synthroid$519$15,80654 claims
Astellas Pharma US IncMyrbetriq$82$5,18312 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$4,550406 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lorain

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →